Literature DB >> 26064198

Prognostic significance of the neutrophil to lymphocyte ratio in patients with non-small cell lung cancer: a systemic review and meta-analysis.

Bin Peng1, Yi-Han Wang1, Yong-Mei Liu1, Lei-Xue Ma1.   

Abstract

Neutrophil to Lymphocyte Ratio (NLR) was recently demonstrated as a useful index in predicting the prognosis of Non-Small Cell Lung Cancer (NSCLC). Thus, a meta-analysis was performed to demonstrate the relationship between NLR and overall survival (OS), progress-free survival (PFS) or disease free survival (DFS) in patients with NSCLC. We searched for relevant literatures in PubMed, EMBASE and Cochrane library and pooled the eligible studies and synthesized hazard ratios (HRs) using Stata 12.0. Final analysis of NSCLC patients from 12 eligible studies was performed. Combined HR suggested that high NLR had an unfavorable effect on patients' OS (n=1700 in 11 studies; HR= 1.43, 95% CI: 1.25-1.64; I^2=80.2%, P<0.01) and PFS (n=664 in 5 studies, HR=1.37, 95% CI: 1.07-1.74; I^2=70.8%, P=0.004). Subgroup analysis based on cutoff shown that, compared with other subgroups, the subgroup with a cutoff of 5 had a significantly poorer survival (HR=1.87, 95% CI 1.49-2.34) with less heterogeneity (I^2=21.3%, P=0.28). However, subgroup analysis based on treatment method indicated that the "surgery" subgroup seemed to have not a significant impact on survival (HR=1.32, 95% CI 0.99-1.77; I^2=80.0%, P=0.063) compared with the chemotherapy subgroup (HR=1.61, 95% CI 1.24-2.10; I^2=82.6%, P<0.01). Additionally, combined odds ratio (OR) suggested high NLR was associated inversely with response to treatment (n = 276 in 2 studies; OR = 1.73, 95% CI: 1.04-2.88; I^2=0%, P=0.40). This study suggests high NLR (especially with a cutoff of 5) seems to be associated with a worse prognosis in patients with NSCLC as well as a worse response to treatments.

Entities:  

Keywords:  NLR; NSCLC; Neutrophil to lymphocyte ratio; non-small cell lung cancer; overall survival; progress-free survival; treatment response

Year:  2015        PMID: 26064198      PMCID: PMC4443032     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  26 in total

1.  Tumour infiltrating lymphocytes in relation to tumour angiogenesis, apoptosis and prognosis in patients with large cell lung carcinoma.

Authors:  A K Eerola; Y Soini; P Pääkkö
Journal:  Lung Cancer       Date:  1999-11       Impact factor: 5.705

2.  Prognostic significance of basic laboratory methods in non- small-cell-lung cancer.

Authors:  Vildan Kaya; Mustafa Yildirim; Ozlem Demirpence; Mustafa Yildiz; Aysen Yesim Yalcin
Journal:  Asian Pac J Cancer Prev       Date:  2013

3.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Authors:  M K Parmar; V Torri; L Stewart
Journal:  Stat Med       Date:  1998-12-30       Impact factor: 2.373

4.  Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.

Authors:  J Danesh; R Collins; P Appleby; R Peto
Journal:  JAMA       Date:  1998-05-13       Impact factor: 56.272

5.  Could the neutrophil to lymphocyte ratio be a poor prognostic factor for non small cell lung cancers?

Authors:  Turgut Kacan; Nalan Akgul Babacan; Metin Seker; Birsen Yucel; Aykut Bahceci; Ayfer Ay Eren; Mehmet Fuat Eren; Saadettin Kilickap
Journal:  Asian Pac J Cancer Prev       Date:  2014

Review 6.  Calcium, cancer and killing: the role of calcium in killing cancer cells by cytotoxic T lymphocytes and natural killer cells.

Authors:  Eva C Schwarz; Bin Qu; Markus Hoth
Journal:  Biochim Biophys Acta       Date:  2012-12-03

7.  Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors.

Authors:  P Lissoni; F Brivio; L Fumagalli; G Messina; V Ghezzi; L Frontini; L Giani; M Vaghi; A Ardizzoia; G S Gardani
Journal:  Int J Biol Markers       Date:  2004 Apr-Jun       Impact factor: 2.659

8.  Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy.

Authors:  Yanwen Yao; Dongmei Yuan; Hongbing Liu; Xiaoling Gu; Yong Song
Journal:  Cancer Immunol Immunother       Date:  2012-09-18       Impact factor: 6.968

9.  Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.

Authors:  Cirino Botta; Vito Barbieri; Domenico Ciliberto; Antonio Rossi; Danilo Rocco; Raffaele Addeo; Nicoletta Staropoli; Pierpaolo Pastina; Giulia Marvaso; Ignazio Martellucci; Annamaria Guglielmo; Luigi Pirtoli; Pasquale Sperlongano; Cesare Gridelli; Michele Caraglia; Pierfrancesco Tassone; Pierosandro Tagliaferri; Pierpaolo Correale
Journal:  Cancer Biol Ther       Date:  2013-06       Impact factor: 4.742

10.  Prognostic importance of the nutritional status and systemic inflammatory response in non-small cell lung cancer.

Authors:  M Yildirim; M Yildiz; E Duman; S Goktas; V Kaya
Journal:  J BUON       Date:  2013 Jul-Sep       Impact factor: 2.533

View more
  60 in total

1.  Diagnostic Value of Neutrophil-Lymphocyte Ratios and Mean Platelet Volumes in the Activation of Recurrent Aphthous Stomatitis.

Authors:  Sinan Uluyol; Saffet Kilicaslan
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-01-12

2.  The role of the neutrophil:lymphocyte ratio (NLR) and the CRP:albumin ratio (CAR) in predicting mortality following emergency laparotomy in the over 80 age group.

Authors:  G Simpson; R Saunders; J Wilson; C Magee
Journal:  Eur J Trauma Emerg Surg       Date:  2017-11-13       Impact factor: 3.693

3.  Fisetin, a dietary bioflavonoid, reverses acquired Cisplatin-resistance of lung adenocarcinoma cells through MAPK/Survivin/Caspase pathway.

Authors:  Wenlei Zhuo; Liang Zhang; Yi Zhu; Bo Zhu; Zhengtang Chen
Journal:  Am J Transl Res       Date:  2015-10-15       Impact factor: 4.060

Review 4.  Immunomethylomics: A Novel Cancer Risk Prediction Tool.

Authors:  Karl T Kelsey; John K Wiencke
Journal:  Ann Am Thorac Soc       Date:  2018-04

5.  Role of Peripheral Blood Markers for Detecting Response and Predicting Prognosis in Patients with Non-small-cell Lung Cancer Undergoing Neoadjuvant Therapy and Surgery.

Authors:  Filippo Lococo; Marco Chiappetta; Jessica Evangelista; Isabella Sperduti; Dania Nachira; Venanzio Porziella; Maria Teresa Congedo; Emilio Bria; Emanuele Vita; Alfredo Cesario; Carolina Sassorossi; Diepriye Charles-Davies; Luca Boldrini; Mariangela Massaccesi; Vincenzo Valentini; Stefano Margaritora
Journal:  Lung       Date:  2022-06-02       Impact factor: 2.584

Review 6.  Neutrophils as potential therapeutic targets in hepatocellular carcinoma.

Authors:  Daniel Geh; Jack Leslie; Rob Rumney; Helen L Reeves; Thomas G Bird; Derek A Mann
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-01-12       Impact factor: 46.802

Review 7.  Biological Rationale for Peripheral Blood Cell-Derived Inflammatory Indices and Related Prognostic Scores in Patients with Advanced Non-Small-Cell Lung Cancer.

Authors:  Giuseppe Luigi Banna; Alex Friedlaender; Marco Tagliamento; Veronica Mollica; Alessio Cortellini; Sara Elena Rebuzzi; Arsela Prelaj; Abdul Rafeh Naqash; Edouard Auclin; Lucia Garetto; Laura Mezquita; Alfredo Addeo
Journal:  Curr Oncol Rep       Date:  2022-10-18       Impact factor: 5.945

Review 8.  Influence of estrogen in non-small cell lung cancer and its clinical implications.

Authors:  Vianey Rodriguez-Lara; Juan-Manuel Hernandez-Martinez; Oscar Arrieta
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

9.  Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis.

Authors:  Zimu Wang; Ping Zhan; Yanling Lv; Kaikai Shen; Yuqing Wei; Hongbing Liu; Yong Song
Journal:  Transl Lung Cancer Res       Date:  2019-06

10.  Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer.

Authors:  Se-Il Go; Mi Jung Park; Haa-Na Song; Myoung Hee Kang; Hee Jung Park; Kyung Nyeo Jeon; Seok-Hyun Kim; Moon Jin Kim; Jung-Hun Kang; Gyeong-Won Lee
Journal:  Support Care Cancer       Date:  2015-11-07       Impact factor: 3.359

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.